Lucid Diagnostics’ esophageal precancer detection tools show efficacy in study

Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced new data from the largest reported real-world experience of non-endoscopic esophageal precancer detection, which evaluated its EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device. The manuscript is currently available on the health sciences preprint server, medRxiv, while undergoing peer review for publication. The study authors concluded that “the largest real-world experience of EsoGuard and EsoCheck to date” demonstrates “excellent safety, tolerability, and scalability… supporting its utility as a non-invasive BE screening tool.” The 18-month retrospective analysis evaluated 11,991 at-risk patients who underwent EsoCheck cell collection and EsoGuard testing in routine clinical practice between January 2023 and June 2024. EsoCheck demonstrated a 95% technical success rate, with 95% of procedures completed in under two minutes and no serious adverse events. The vast majority of patients met U.S. gastroenterology society guideline criteria for BE screening, reflecting appropriate physician use of EsoGuard in routine practice.